Supervisory Board Member
Dr. Barbara Gansewendt*
Member of the Supervisory Board effective April 2022, elected until 2027
Chairwoman of the Bayer Group Executives´ Committee
Chairwoman of the Executives´ Committee of Bayer AG, Wuppertal
*employee representative
Curriculum Vitae
| September 29, 1963 | born in Bocholt, grown up in Dortmund, Germany |
| 1982–1987 | Pharmacy studies at University of Muenster with mandatory pharmacy internship in Göttingen |
| 1987 | State Accreditation as Pharmacist |
| 1988–1992 | Toxicology Research associate / Postdoctoral Research Fellow in toxicology at IfADo – Leibniz Research Centre for Working Environment and Human Factors, Dortmund, Germany |
| 1990 | PhD Graduation: Doctorate in pharmaceutical chemistry granted from University of Muenster |
| 1992 | Registered Toxicologist (DGPT and EuroTox) |
| 1992 | Joined Bayer AG and held different positions in Drug Regulatory Affairs since then |
| 1992–1999 | Regulatory Affairs Project Leader (Bayer Vital GmbH & Co KG, Leverkusen) |
| 2000–2002 | Global Regulatory Affairs Manager (Bayer Pharma AG, Wuppertal) |
| 2002–2004 | European RA Strategy Leader (Bayer Healthcare AG, Wuppertal) |
| 2004–2010 | Head of Regulatory Affairs Germany, Pharma (Bayer Vital GmbH, Leverkusen) |
| 2010–2022 | VP, Global Head of Regulatory Submission Management (Bayer AG, Wuppertal) |
| since 2022 | Senior Advisor Regulatory Affairs (Bayer AG, Wuppertal) |
| 2006–2019 | Board Member (Treasurer) of the German Society of Drug Regulatory Affairs (DGRA), Bonn |
| since 1992 | Member of the Association of Academic Employees (VAA) |
| since 2014 | Member of the Executives´ Committee Bayer AG Wuppertal |
| since 2015 | Chairwoman of the Executives´ Committee Bayer AG Wuppertal und Member of the Bayer Group Executives´ Committee |
| 2018–2022 | Vice Chairwoman of the Bayer Group Executives‘ Committee |
| since 2022 | Chairwoman of the Bayer Group Executives‘ Committee |